重组CHO乙型肝炎疫苗免疫后26年保护效果及回忆应答的随访研究
2024年在河北正定县开展的横断面调查,评估中国仓鼠卵巢(CHO)细胞来源乙型肝炎疫苗(CHO-HepB)26年保护效果及加强接种后6.5年回忆应答。队列I(178人)HBsAg阳性率0.56%、抗-HBc阳性率1.12%、抗-HBs阳性率64.61%,估算疫苗保护率约95.0%;队列II(97人)加强后6.5年抗-HBs阳性率从87.6%降至51.5%。结论:CHO-HepB至少保护26年,普通人群可能无需常规加强,高危人群可针对性加强。
要点
- 队列I接种后25.7年HBsAg阳性率0.56%,估算疫苗保护率约95.0%。
- 接种后7-26年HBsAg和抗-HBc阳性率无显著增加,抗-HBs阳性率显著下降。
- 队列II加强后6.5年抗-HBs阳性率从87.6%降至51.5%,但无新发感染。
核心结论
- CHO-HepB至少提供26年持久保护,尽管抗-HBs水平下降,未观察到新发感染或携带者。
- 普通人群可能无需常规加强接种,但高危人群针对性加强有助于维持群体免疫并避免未来暴发。
- 持续重视预防母婴传播对乙型肝炎控制仍至关重要。
研究设计与样本
- 2024年在河北正定县开展的横断面调查,评估CHO-HepB的26年保护效果及加强接种后6.5年回忆应答。
- 队列I为178名1997年和1999年出生、出生时接种标准三剂次且未再加强者,距接种平均间隔25.7年。
- 队列II为97名2018年接受加强接种者。
主要发现
- 队列I的HBsAg阳性率为0.56%(95%CI:0-1.66%),抗-HBc阳性率为1.12%(95%CI:0-2.67%),抗-HBs阳性率为64.61%(95%CI:57.88-71.34%)。
- 队列I中115名阳性者的几何平均浓度(GMC)为84.93 mIU/mL(95%CI:65.99-109.31)。
- 对照当地历史HBsAg流行率11.3%,估算疫苗保护率约为95.0%。
- 2005、2009、2013、2017和2024年同队列系列调查显示,接种后7-26年HBsAg或抗-HBc阳性率无显著增加(均P>0.05),而抗-HBs阳性率显著下降(P<0.05)。
- 队列II加强后6.5年,无人HBsAg或抗-HBc转阴,但抗-HBs阳性率从87.6%降至51.5%,GMC相应下降。
关键数值与推荐
- 队列I接种后25.7年HBsAg阳性率0.56%(95%CI:0-1.66%),抗-HBc阳性率1.12%(95%CI:0-2.67%),抗-HBs阳性率64.61%(95%CI:57.88-71.34%)。
- 队列I中115名阳性者GMC为84.93 mIU/mL(95%CI:65.99-109.31)。
- 对照历史HBsAg流行率11.3%,估算疫苗保护率约95.0%。
- 队列II加强后6.5年抗-HBs阳性率从87.6%降至51.5%。
临床怎么用
- 作者认为普通人群可能无需常规加强接种,但高危人群可针对性加强以维持群体免疫并避免未来暴发。
- 作者强调持续重视预防母婴传播对乙型肝炎控制仍至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 2024 cross-sectional survey in Zhengding County, Hebei, evaluated the 26-year protective efficacy of the Chinese hamster ovary (CHO) cell-derived hepatitis B vaccine (CHO-HepB) and 6.5-year anamnestic response to booster vaccination. Cohort I comprised 178 participants born 1997 and 1999 who had received the standard three-dose series at birth and no subsequent booster. Their mean interval since vaccination was 25.7 years. HBsAg, anti-HBc, and anti-HBs positivity rates were 0.56 % (95 % CI: 0-1.66 %), 1.12 % (95 % CI, 0-2.67 %) and 64.61 % (95 % CI, 57.88-71.34 %), respectively. Among 115 positive individuals, the geometric mean concentration (GMC) was 84.93 mIU/mL (95 % CI, 65.99-109.31). Against a historical local HBsAg prevalence of 11.3 %, the estimated vaccine protection rate was approximately 95.0 %. Serial surveys of the same cohort conducted in 2005, 2009, 2013, 2017, and 2024 revealed no significant increase in HBsAg or anti-HBc positivity over 7-26 years post-vaccination (both P > 0.05), whereas anti-HBs positivity declined significantly (P < 0.05). Cohort II included 97 individuals who received a booster in 2018. After 6.5 years, none were HBsAg or anti-HBc-negative; however, anti-HBs positivity fell from 87.6 % to 51.5 %, and GMCs declined accordingly. In conclusion, CHO-HepB confers durable protection for at least 26 years, with no new infections or carriers observed despite waning anti-HBs levels. Routine booster does may be unnecessary for the general population, yet targeted boosting could help sustain herd immunity and avert future outbreaks, particularly in high-risk populations. Continued emphasis on preventing mother-to-child transmission remains essential for hepatitis B control.
引用
- Kang W, Wang F, Hao Z, et al. A follow-up study on the protective efficacy and anamnestic response of recombinant CHO hepatitis B vaccine 26 years after immunization. Vaccine. 2025. PMID: 40945180. doi:10.1016/j.vaccine.2025.127743
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。